HWHG: Oxcarbazepine extended-release tablets received a tentative approval number from the U.S. FDA

Zhitong

Sep 19, 2025 at 02:38 AM

I'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, HWHG announced that its holding subsidiary, Wuhan Renfulikang Pharmaceutical Co., Ltd. (referred to as "Renfulikang"), has received a tentative approval number from the U.S. Food and Drug Administration (FDA) for Oxcarbazepine Extended-Release Tablets. Oxcarbazepine Extended-Release Tablets are used to treat partial seizures in patients aged 6 years and older with epilepsy

According to the Zhitong Finance APP, HWHG (600079.SH) announced that its controlling subsidiary, Wuhan Renfulikang Pharmaceutical Co., Ltd. (referred to as "Renfulikang"), has received a tentative approval number from the U.S. Food and Drug Administration (FDA) for Oxcarbazepine Extended-Release Tablets. Oxcarbazepine Extended-Release Tablets are used to treat partial seizures in patients aged 6 years and older with epilepsy

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.